Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses.

Mednet Member

Medical Oncology · University of Chicago

Short answer is - yes! Long answer is - it depends. Patients can be optimized leading into CAR T-cell therapy by using ESAs and possible TPO agonists, iron, B12, folate supplementation. The main issue is around propensity for anemia and thrombocytopenia, especially if profound and prolonged. Patient...